National Comprehensive Cancer Network recommendations for monitoring response to tyrosine kinase inhibitors (TKI) treatment are not being consistently followed in patients with chronic phase-chronic myeloid leukemia (CP-CML), according to an international observational study involving >1,200 individuals. Participants had CP-CML and received first-line treatment with TKIs. Investigators looked at use and management patterns in the US and Europe. Among the results:
- 8 in every 10 patients had baseline comorbidities.
- Monitoring for either cytogenetic or molecular responses (CyR/MR) improved over time.
- 36% were monitored at 3 months; 82% at 6 months; and 95% at 1 year.
- 5% had no record of CyR/MR monitoring in the first year of therapy.
- Documentation of CyR/MR testing was lower in the US than in Europe.
- It was also lower in community vs academic practices.
- Patients <65 years of age, treated at academic centers, and no longer on first-line therapy were more likely to be monitored by 1 year.
Goldberg S, Cortes J, Gambacorti-Passerini C, et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. [Published online ahead of print August 17, 2017]. Am J Hematol. doi:10.1002/ajh.24887.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al